Peptide Sciences — one of the largest and most recognizable grey market research peptide vendors — has voluntarily shut down operations and discontinued all product sales. The announcement appeared on their website in early March 2026.
What Happened
Peptide Sciences posted a brief announcement stating the decision to shut down was made "voluntarily." No detailed explanation was provided, but context from the broader industry paints a clear picture of mounting pressure.
Contributing Factors
Finnrick Testing Results Finnrick Analytics tested 37 samples of Peptide Sciences' retatrutide and gave it an **E rating** — the lowest possible grade. For a vendor that charged premium prices and built their brand on quality, this was significant brand damage. When the most expensive vendor in the market gets the worst possible purity grade on an independently tested compound, the credibility gap becomes impossible to close.
FDA Regulatory Pressure The FDA has been escalating enforcement against grey market peptide vendors throughout 2025-2026: - Warning letters to vendors selling unapproved peptide products - Seizures of shipments at customs - Public advisories about health risks from unregulated peptides
The Market Is Shifting Peptide Sciences isn't an isolated case. The grey market research peptide model is under pressure from multiple directions:
- •Trustpilot flagged several major peptide vendor profiles as "not a good fit" — effectively removing their review histories. Vendors affected include Swiss Chems, Pure Rawz, Biotech Peptides, Core Peptides, NextChems, Simple Peptide, and others.
- •RFK Jr. announced that approximately 14 peptides on the FDA Category 2 list will move to Category 1, allowing legal compounding by licensed pharmacies. This makes the grey market vendor model less necessary.
- •Hims & Hers acquired a dedicated peptide manufacturing facility in 2025 and announced peptide product development on their February 2026 earnings call.
- •Telehealth peptide clinics are expanding, offering prescribed peptides from FDA-registered compounding pharmacies.
What This Means for the Industry
Dr. Murphy, writing on Substack about the shutdown, identified three possible market responses:
- 1.Fragmentation: Smaller vendors fill the gap with less transparency
- 2.Offshore movement: Supply chains relocate to regions with weaker enforcement
- 3.Regulated transition: The market shifts toward pharmacy-grade manufacturing and physician supervision
We believe option 3 is what's happening. The combination of regulatory pressure, the RFK reclassification announcement, and major companies like Hims entering the peptide space all point toward legitimate, prescribed access replacing the grey market model.
Your Options Going Forward
Research Vendors That Still Operate Several research peptide vendors remain operational. Based on our scoring:
- •Particle Peptides — 4.7/5 Trustpilot rating
- •Peptide Crafters — Finnrick A-rated, 4.5/5 Trustpilot
- •BioLongevity Labs — Triple third-party testing
But be aware: the regulatory environment is not getting friendlier for grey market vendors.
Telehealth Peptide Clinics Legitimate telehealth services prescribe peptides through licensed clinicians, sourced from FDA-registered compounding pharmacies. This costs more but provides:
- •Legal access — prescribed by a licensed doctor
- •Verified purity — FDA-registered pharmacies test for purity, potency, and sterility
- •Medical oversight — dosing guidance and monitoring
- •No seizure risk — legitimate prescriptions shipped legally
We're building out our [clinics section](/clinics) with independent reviews of telehealth peptide providers.
Wait for Compounding Reform With 14 peptides expected to move to Category 1 status, compounding pharmacies may soon legally prepare BPC-157, TB-500, and other popular compounds. This could dramatically increase access and reduce prices through legitimate channels. See our [full regulatory timeline](/blog/fda-peptide-compounding-timeline) for details.
The Bottom Line
Peptide Sciences shutting down is a signal, not a surprise. The grey market model — selling unregulated research chemicals through websites with "not for human consumption" disclaimers — was always on borrowed time. The future is prescribed peptides through legitimate medical channels, and that future is arriving faster than most people expected.
Updated March 7, 2026. Sources include Finnrick Analytics testing data, FDA.gov, and industry reporting from Dr. Murphy (Substack) and Hims House (X/Twitter).